



**QUEEN'S
UNIVERSITY
BELFAST**

Induction of prostaglandin endoperoxide synthase 2 by mitogen-activated protein kinase cascades

McGinty, A., Foschi, M., Chang, Y. E., Han, J., Dunn, M. J., & Sorokin, A. (2000). Induction of prostaglandin endoperoxide synthase 2 by mitogen-activated protein kinase cascades. *Biochemical Journal*, 352(2), 419-424.

Published in:
Biochemical Journal

Queen's University Belfast - Research Portal:
[Link to publication record in Queen's University Belfast Research Portal](#)

General rights

Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.

Induction of prostaglandin endoperoxide synthase 2 by mitogen-activated protein kinase cascades

Ann MCGINTY^{*1,2}, Marco FOSCHI^{*1,3}, Yu-Wen E. CHANG^{*}, Jiahuai HAN[†], Michael J. DUNN^{*} and Andrey SOROKIN^{*4}

^{*}Department of Medicine and Cardiovascular Research Center, Medical College of Wisconsin, 8701 Watertown Plank Rd, Milwaukee, WI 53226-0509, U.S.A., and

[†]Department of Immunology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, U.S.A.

Prostaglandin endoperoxide synthase (PGHS) catalyses the rate-limiting step in the formation of prostaglandin and thromboxane eicosanoids from arachidonic acid released by phospholipase A₂. Two forms of PGHS exist, PGHS-1 and PGHS-2. PGHS-2, normally absent from cells, is rapidly expressed in response to a wide variety of stimuli and has been implicated in the pathogenesis of colon cancer and several inflammatory diseases. The three principal mitogen-activated protein kinase (MAPK) pathways are the extracellular signal-regulated protein kinase (ERK), the c-Jun N-terminal kinase (JNK) cascade and the p38-MAPK cascade. The present study was undertaken to investigate the putative involvement of the MAPK cascades in PGHS-2 induction. The potential role of ERK in PGHS-2 up-regulation was assessed by using cell lines expressing, both stably and after adenoviral infection, constitutively active forms of its upstream activator MAPK/ERK kinase (MEK1). The possible involvement of JNK and p38-MAPK in positively modulating PGHS-

2 transcription was investigated by using adenovirus-mediated transfer of active forms of their respective specific upstream kinases, mitogen-activated protein kinase kinase (MKK) 7 and MKK3/MKK6. ERK activation promoted the induction of PGHS-2 mRNA and protein. Similarly, activation of JNK by Ad-MKK7D and p38-MAPK by Ad-MKK3bE/Ad-MKK6bE resulted in the increased expression of PGHS-2. These results provide evidence that activation of all three of the major mammalian MAPK leads to the induction of PGHS-2 mRNA and protein. Because PGHS-2 is up-regulated by a diverse range of stimuli, both mitogenic and stress-evoking, these results provide evidence that the convergence point of these stimuli could be the activation of one or more MAPK cascade(s).

Key words: colon cancer, inflammation, signal transduction, transcriptional up-regulation.

INTRODUCTION

Prostaglandin endoperoxide synthase (PGHS) is the enzyme that catalyses the first, rate-limiting step in the formation of prostaglandins from arachidonic acid released by phospholipase A₂ [1]. Two forms of PGHS have been characterized, PGHS-1 and PGHS-2. PGHS-2, normally absent from cells, is rapidly expressed in response to a wide variety of stimuli [1]. Expression of PGHS-2 is elevated in colonic tumours [2–4]; genetic evidence has been provided that PGHS-2 expression is causal in the development of colon polyps and carcinoma [5]. In addition, PGHS-2 has been implicated in both the promotion [6] and resolution [7] of inflammation.

It has been reported that the HCT-116 cancer cell line both expresses elevated levels of PGHS-2 in the basal condition and also has the capacity to drive the expression of a PGHS-2-promoter-luciferase construct [8]. This result lends support to the hypothesis that elevated PGHS-2 expression in colonic cancer might be due to dysregulated transcription and would suggest that a transcription factor aberrantly over-activated (or over-expressed) in carcinoma cells facilitates the abnormal expression

of PGHS-2. Alternatively, a negative regulator of PGHS-2 transcription might be lost or non-functional in these cells. The promoter/enhancer region of the various mammalian PGHS-2 genes share a number of modulatory elements, including cAMP-response element (CRE), nuclear factor (NF)-IL6, NF-κB and activator protein 2 [9]. The first three of these consensus sequences have been implicated in ligand-dependent up-regulation of the human enzyme [9–12]; in addition it has been proposed that p53 might negatively regulate PGHS-2 expression by binding to the TATA sequence (located between –13 and –26 bp in the human gene) [13].

The three principal mitogen-activated protein kinase (MAPK) pathways are the extracellular signal-regulated protein kinase (ERK), the c-Jun N-terminal kinase (JNK) and the p38-MAPK cascades [14]. These cascades consist of a three-kinase module composed of the tertiary kinase or MAPK (ERK, JNK and p38-MAPK), activated by a MAPK/ERK kinase (MEK, also referred to as MAPK kinase or MKK), which in turn is activated by a MEK kinase (MEKK). ERK is activated by MEK, which is activated by Raf, the prototypic mammalian MEKK. JNK is activated by MKK4 and MKK7, and p38-MAPK by MKK4,

Abbreviations used: C/EBP, CCAAT-enhancer-binding protein; CRE, cAMP-response element; ERK, extracellular signal-regulated protein kinase; FBS, fetal bovine serum; HUVEC, human umbilical-vein endothelial cells; JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; MEK, MAPK/ERK kinase; MEKK, MEK kinase; MOI, multiplicity of infection; NF, nuclear factor; PGHS, prostaglandin endoperoxide synthase; SV40, simian virus 40; tHMC, SV40-transformed human mesangial cells.

¹ These authors contributed equally to the work.

² Present address: Department of Surgery, The Queen's University of Belfast, Institute of Clinical Science, The Royal Group of Hospitals, Grosvenor Road, Belfast, BT12 6BJ, Northern Ireland, U.K.

³ Present address: Dipartimento di Medicina Interna, Università Degli Studi di Firenze, Viale Morgagni 85, I-50134 Firenze, Italy.

⁴ To whom correspondence should be addressed (e-mail sorokin@mcw.edu).

MKK3 and MKK6 [14–20]. In addition, evidence exists that MKK3, MKK4, MKK6 and MKK7 can be activated by MEKK1–3 [14,16]. The ERK pathway is mobilized by a wide range of extracellular stimuli, including G-protein-coupled ligands, growth factors and cytokines; activation of this pathway is integral to the signalling of agents evoking cellular proliferation and differentiation. The stress-activated MAPK, JNK and p38-MAPK have been shown to have pivotal roles in cellular response to both extracellular and intracellular stress; in contrast with ERK, their activation generally promotes growth inhibition and induces apoptosis [14].

ERK, JNK and p38-MAPK are activated by many of the diverse stimuli capable of inducing PGHS-2 expression [14]. Moreover, the regions of the human PGHS-2 proximal promoter that have been shown to be involved in mediating the up-regulation of this enzyme bind a number of MAPK-activated transcription factors [9,14]. In the current study we therefore investigated the ability of the three principal MAPKs to drive PGHS-2 up-regulation. The putative role of ERK in mediating PGHS-2 transcription was studied by using cell lines expressing constitutively active forms of its upstream activator MEK1 (also known as MKK1) [14]. The possible modulation of PGHS-2 expression by JNK and p38-MAPK was investigated by means of adenovirus-mediated transfer of constitutively active MKK7 [15–18] and MKK3/MKK6 [19,20] constructs.

EXPERIMENTAL

Materials

All cell culture reagents and routine biochemicals were obtained from Sigma Chemical Co. (St Louis, MO, U.S.A.). Anti-MEK and anti-(phospho-MAPK) [anti-(phospho-JNK) and anti-(phospho-p38-MAPK)] antibodies were from New England Biolabs (Beverly, MA, U.S.A.). Anti-(PGHS-2) antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, U.S.A.). Enhanced chemiluminescence (ECL[®]) kits were obtained from Amersham (Piscataway, NJ, U.S.A.). Protein determinations were performed by means of a bicinchoninic acid assay obtained from Pierce (Rockford, IL, U.S.A.). A plasmid containing a full-length 4.2 kb PGHS-2 insert was kindly provided by Dr Harvey Herschman (Los Angeles, CA, U.S.A.). The *MEK1* constructs used in adenoviral generation and NIH 3T3 cells expressing *MEK1* constructs were kindly provided by Dr Nathalie Ahn (Boulder, CO, U.S.A.).

Stable cell lines

Parental NIH 3T3 fibroblasts and stably transfected cell lines derived from these were propagated in Dulbecco's modified Eagle's essential high-glucose medium, supplemented with 10% (v/v) heat-inactivated calf serum, 100 i.u./ml penicillin and 100 µg/ml streptomycin. Cell lines expressing the pSV2neo vector or pMM9 vector constructs encoding constitutively active MEK1 (Δ N3/S222D; deletion of a predicted α -helix encompassing residues 32–51 and replacement of the regulatory Ser-222 residue with Asp), wild-type MEK1 and catalytically inactive MEK1 (K97M) under the control of the Maloney sarcoma virus long terminal repeat are as described previously [21]. Cells were made quiescent for 24 h before experiments.

Recombinant adenoviral vectors

A second catalytically active MEK1 construct (Δ N3/S218E-S222D, achieved by the replacement of both regulatory residues, Ser-218 and Ser-222, with glutamic and aspartic residues re-

spectively and the deletion of a predicted α -helix encompassing residues 32–51 [21]) was incorporated into the recombinant adenoviral vector AdMEK_{CA}. AdMEK_{CA} was constructed from the replication-deficient adenovirus type 5 (Ad5) with deletions in the E1 and E3 genes (Ad-d1327), and a plasmid containing Ad5 sequences from bp 22 to bp 5790 with a deletion of the E1 region from bp 342 to bp 3523, a polycloning site under the control of the CMV promoter, the mutated human MEK1 gene and the simian virus 40 (SV40) polyadenylation signal [22]. The recombinant adenoviral constructs encoding activated MKK6 (Ad-MKK6bE), MKK3 (Ad-MKK3bE) and MKK7 (Ad-MKK7D) have been described previously [23–25].

Adenoviral infection

Human umbilical-vein endothelial cells (HUVEC) were cultured in MCDB 105 medium containing 20% (v/v) fetal bovine serum (FBS) and endothelial cell growth supplement (80 µg/ml). HUVEC were rendered quiescent overnight in MCDB medium containing 1% (v/v) FBS. Cells were infected with Ad-MEK_{CA} and the non-transgenic control virus Ad-d1327 at a multiplicity of infection (MOI) of 60, essentially as described previously [22]. The adenovirus-mediated gene transfer of MEK1 was verified by Western blot analysis of cell lysates with anti-MEK antibodies and the concomitant activation of ERK by means of an immunocomplex assay. At various time points after infection, total RNA was isolated and Northern analysis for PGHS-2 mRNA was performed.

For experiments with Ad-MKK7D and Ad-MKK3bE/MKK6bE, SV40-transformed human mesangial cells (tHMC) [22,26] were rendered quiescent for 24 h before being infected with Ad-MKK7D at a MOI of 100, with Ad-MKK3bE/MKK6bE at a MOI of 50/50 or with a control adenovirus encoding β -galactosidase (Ad-LacZ) at a MOI of 100, as described previously [22]. After 36 h the cells were lysed and the resultant cell lysates were subjected to a Western blot analysis with phospho-specific anti-JNK and anti-(p38-MAPK) antibodies. Having thus confirmed adenoviral transfer and the consequent activation of JNK and p38-MAPK, Western blot analysis of PGHS-2 expression was performed.

RNA extraction and Northern blot analysis

Total cellular RNA was isolated by the acid guanidinium thiocyanate method [27] and analysed exactly as described elsewhere [28].

Western analysis and immunocomplex assays

Western blot analysis and MAPK immunocomplex assays were performed exactly as described previously [29]. For ERK assays, samples standardized for protein (400 µl, prepared as described above) were immunoprecipitated with a polyclonal antibody against p42 ERK [29]. After incubation with Protein A-Sepharose, samples were washed twice with lysis buffer and twice with kinase assay buffer (20 mM Hepes, pH 7.4, containing 10 mM MgCl₂ and 200 µM orthovanadate) before being resuspended in 60 µl of kinase buffer containing 0.25 mg/ml myelin basic protein, 50 µM ATP and 5 µCi of [γ -³²P]ATP. The reaction was initiated by incubation at 30 °C for 15 min and terminated by the addition of 60 µl of Laemmli buffer. The samples were then subjected to SDS/PAGE [12% (w/v) gel], followed by autoradiographic development.

RESULTS AND DISCUSSION

Activation of each of the three major MAPK cascades (ERK, JNK and p38-MAPK) results in the mobilization of numerous transcription factors and the up-regulation of target genes [14]. Here we present results that support the hypothesis that the induction of PGHS-2 expression in response to a variety of stimuli might be secondary to the activation of one or more of the three major MAPK cascades.

Investigations employing pharmacological MEK inhibitors have provided evidence that the ERK pathway is involved in PGHS-2 induction [30,31]. In addition, it has been reported that the overexpression of both wild-type ERK-1 and ERK-2 potentiates v-Src-mediated activation of a murine PGHS-2 promoter construct and have speculated that this might occur in an




Figure 1 Fibroblasts transfected with the constitutively active MEK1 mutant demonstrate an increased level of PGHS-2 protein

pSVneo-transfected cells are shown unstimulated and after stimulation with endothelin-1 (ET-1; 100 nM, for 22 h). Quiescent cells stably expressing constitutively active MEK1 (Δ N3/S222D) demonstrated PGHS-2 expression at a level comparable to that induced in mock-transfected cells by ET-1. Shown is a representative experiment; the experiment was performed at least three times.

Elk-1-dependent manner [32]. The putative role of ERK in PGHS-2 induction was assessed in the current study by using both cell lines stably transfected, and primary cells adenovirally infected, with constitutively active *MEK1* constructs. The NIH 3T3 Δ N3/S222D cell line is invaluable for studying the downstream targets of ERK activation because this MAPK pathway is continuously activated in these cells, independently of extracellular stimuli. Cells stably expressing MEK Δ N3/S222D exhibit greatly enhanced basal ERK activity when compared with cells transfected with vector only (*pSV2neo*) or cells expressing wild-type or catalytically inactive (K97M) MEK1 ([21], and results not shown). Correspondingly, levels of PGHS-2 protein [as assessed by probing cell lysates normalized with regard to protein with anti-(PGHS-2) antiserum] in quiescent NIH 3T3 Δ N3/S222D cells were found to be elevated in comparison with cells transfected with vector only (*pSV2neo*) or cells expressing wild-type or catalytically inactive MEK1 (Figure 1). Δ N3/S222D 3T3 cells also demonstrated constitutive up-regulation of PGHS-2 mRNA (results not shown); however, to determine the time course of PGHS-2 mRNA induction in response to ERK activation, an adenoviral construct encoding a second catalytically active MEK1 mutant, Δ N3/S218E-S222D, was employed and this, together with a control adenovirus construct, was used to infect HUVEC. Adenovirus-mediated MEK1 expression was confirmed by Western analysis (Figure 2, left-hand top panel) and the activation of ERK in cells infected with Ad-MEK_{CA} was verified by immunocomplex assay (Figure 2, left-hand middle panel). In agreement with the results obtained from the Δ N3/S222D fibroblast cell line, adenovirus-mediated constitutively active MEK1 expression also led to increased PGHS-2 protein expression (Figure 2, left-hand bottom panel). Northern analysis with a full-length PGHS-2 cDNA probe revealed that, in comparison with control virus-infected HUVEC, cells transfected with Ad-MEK_{CA} exhibited an induction of PGHS-2 mRNA within 3 h of infection; this was increased at 6 and 9 h (Figure 2, right-hand panel).




Figure 2 HUVEC infected with Ad-MEK_{CA} exhibit increased MEK protein expression, ERK activation, induction of PGHS-2 mRNA and PGHS-2 protein expression

Cell lysates of HUVEC infected with adenovirus encoding constitutively active MEK (N3/S218E-S222D) for 6 h (Ad-MEK_{CA}) or control cells (uninfected) were subjected to SDS/PAGE and Western blot analysis with anti-MEK antibodies (left-hand top panel). Lysates were subjected to a confirmatory immunocomplex assay for ERK activity (left-hand middle panel). As a positive control, uninfected cells were stimulated with 20% (v/v) FBS for 5 min (uninfected, 20% FBS). The positions of MEK1 and MBP (myelin basic protein) are indicated. Expression of PGHS-2 in these cell lysates was determined by Western analysis with anti-(PGHS-2) antiserum (left-hand bottom panel). At the various time points shown after the infection of HUVEC with AdMEK_{CA} or control Ad-DL327 (lanes corresponding to cells that received no adenovirus are indicated as uninfected), total cellular RNA was isolated and Northern blot analysis was performed with PGHS-2 cDNA (right-hand upper panel). After stripping of the membrane, it was rehybridized with a glyceraldehyde-3-phosphate dehydrogenase (GAPDH) probe to confirm even loading of RNA (right-hand lower panel).




Figure 3 Stress-activated MAPK activation and PGHS-2 expression are increased after infection of tHMC with Ad-MKK3bE/Ad-MKK6bE and Ad-MKK7D

Cell lysates of tHMC infected with Ad-LacZ, Ad-MKK3bE/Ad-MKK6bE or Ad-MKK7D for 36 h were subjected to SDS/PAGE and Western blot analysis with anti-(PGHS-2) antibodies (top panel), anti-(phospho-JNK) antibodies (middle panel) or anti-(phospho-p38-MAPK) antibodies (lower panel). The positions of PGHS-2, phospho-JNK and phospho-p38-MAPK are indicated. Shown is a representative experiment; the experiment was repeated twice with similar results.

These results indicate that the sustained activation of ERK by two distinct catalytically active MEK1 mutants results in the up-regulation of PGHS-2 in both fibroblasts and HUVEC; taken together, the results support a role for activated ERK in the transcriptional up-regulation of PGHS-2. In addition to Elk-1, ERK has also been reported to phosphorylate and activate NF-IL6 [also known as CCAAT-enhancer-binding protein (C/EBP) β] [33]. Although the consensus motif for this transcription factor has been shown to be involved in the induction of human PGHS-2, this seems to be mediated via the binding of C/EBP δ [10]. NF-IL6 has been shown to regulate c-Fos expression [34] and thus, like Elk-1, might well have a role in the potentiation of PGHS-2 expression. The present results provide novel evidence *in vitro* that activated ERK is capable of not only potentiating [32] but actually effecting PGHS-2 transcription.

To assess the putative involvement of the stress-activated MAPK in the modulation of PGHS-2 expression, adenoviral constructs encoding constitutively active variants of their respective specific activating kinases were employed. MKK7 has been demonstrated to be a specific activator of the JNK family kinases [15–18], whereas p38-MAPK is the principal target of MKK3 and MKK6 [19,20]. tHMC were infected with equal adenoviral titres of Ad-MKK7D or a combination of Ad-MKK3bE and Ad-MKK6bE. Although Ad-MKK3bE and Ad-MKK6bE can each activate p38-MAPK independently, by using a combination of the two adenoviral constructs the possibility of isoform-specific activation of p38-MAPK by one or other of these MKKs is overcome [24]. Successful adenoviral transfer and activity were confirmed by means of Western blot analysis of phosphorylated, and hence activated, JNK and p38-MAPK by using phospho-specific antibodies (Figure 3). As can be seen, infection with Ad-MKK7D led to a marked activation of both the p46 and p54 JNK isoforms but had virtually no effect on the activation status of p38-MAPK (Figure 3, middle and bottom panels). Similarly, infection with Ad-MKK3bE/Ad-MKK6bE resulted in a significant activation of p38-MAPK without having any effect on either JNK isoform (Figure 3, middle and bottom panels). Cells transduced with Ad-LacZ exhibited no activation of either JNK or p38-MAPK (Figure 3, middle and bottom panels) and none of the three adenoviral constructs was found to activate ERK (results not shown).

Having thus confirmed the substrate specificity of the adenoviral constructs, the expression of PGHS-2 in tHMC cell lysates was also assessed by Western blotting. Infection of tHMC with either Ad-MKK7D or an Ad-MKK3bE/Ad-MKK6bE combination (with the consequent constitutive activation of JNK and p38-MAPK respectively) led to a marked increase in the expression of PGHS-2, whereas infection with Ad-LacZ had no effect on PGHS-2 protein levels (Figure 3, top panel). These results confirm that both stress-activated MAPKs are capable of driving PGHS-2 transcription. It has been reported that MEKK-1-dependent JNK activation results in the activation of a murine PGHS-2 promoter construct [32,35]. Guan et al. [36] reported that activation of the MEKK-1/MKK4 module up-regulates PGHS-2 expression via the concomitant activation of JNK and p38-MAPK; interestingly, they also found that the over-expression of a constitutively active MEKK-1 mutant resulted in the activation of MKK4 but not MKK3 or MKK6. Significantly, in the present study, novel evidence is given that the stress-activated MAPKs can each independently drive PGHS-2 expression and that this occurs in a MKK7-dependent and MKK3/6-dependent manner.

JNK phosphorylates c-Jun on its N-terminal activating domain [37], thereby inducing the formation of c-Jun homodimers and c-Jun–c-Fos heterodimers and leading to up-regulated transcription activity of numerous genes via activator protein 1 and CRE sites [38,39]. Studies have indicated that the CRE site of human PGHS-2 is involved in C/EBP-mediated up-regulation [10] and it has been reported that this site also facilitates the c-Jun-driven transcription of human and murine PGHS-2 [32,35,40]. Similarly, although p38-MAPK has been reported to activate a number of transcription factors [14] and to be involved in PGHS-2 up-regulation [36], the precise mechanism by which this MAPK facilitates PGHS-2 expression is as yet undetermined.

With regard to the potential role of MAPK cascades in effecting constitutive PGHS-2 expression in colonic cancer, ERK activation has been paralleled with tumorigenic progression in rat intestinal neoplasia [41] and it has been reported that pharmacological MEK inhibition significantly suppresses colonic tumour growth *in vitro* and *in vivo* [42]. In contrast, Wang and co-workers concluded that the ERK1/2 activity was down-regulated in colorectal tumour in comparison with adjacent normal tissue [43], and other investigators have correlated decreased ERK expression and activity with the progression of normal gastric tissue to adenoma [44,45]. Although our own investigations have confirmed tumour-associated PGHS-2 expression, we did not detect enhanced ERK activation in human colon cancer samples in comparison with control tissue (results not shown). In addition, although tumour tissue from five of eight patients exhibiting neoplasia-associated PGHS-2 had increased levels of JNK activity, and p38-MAPK displayed a tentative trend towards tumour-associated phosphorylation (results not shown), these results were far from unequivocal. Although JNK activation has been paralleled with tumorigenic progression in rat intestinal neoplasia [41], Wang and co-workers have reported that the activities of both JNK1 and p38-MAPK were in fact down-regulated in colorectal tumours in comparison with normal tissue [43]. It therefore seems that the role of ERK, JNK and p38-MAPK in the pathogenesis of colon cancer is still unclear and that, by extrapolation, so too does the involvement of these MAPKs in driving tumour-associated PGHS-2 expression.

In conclusion, the findings of the present study provide evidence that MAPK cascades are the convergence point of the numerous diverse stimuli that have been reported to up-regulate PGHS-2. However, although the ligand-dependent activation of

one or more of these cascades might drive pathogenic expression of PGHS-2 in, for example, inflammatory models [46], the role of MAPK in mediating colon-cancer-associated expression of this enzyme remains to be established.

This work was supported by National Institute of Health Research Grants DK 41684 (to A. S.) and HL 22563 (to M.J.D.), by an Interdisciplinary Research Project Grant from MCW Cancer Center (to A. S.), by a Health Research Board (Republic of Ireland) Project Grant (to A.McG.) and by a grant from MURST and the University of Florence (to M.F.).

REFERENCES

- Hla, T., Bishop-Bailey, D., Liu, C. H., Schaefer, H. J. and Trifan, O. C. (1999) Cyclooxygenase-1 and -2 isoenzymes. *Int. J. Biochem. Cell Biol.* **31**, 551–557
- Sano, H., Kawahito, Y., Wilder, R. L., Hashimoto, A., Mukai, S., Asai, K., Kimura, S., Kato, H., Motoharu, K. and Hla, T. (1995) Expression of cyclooxygenase-1 and -2 in human colorectal cancer. *Cancer Res.* **55**, 3785–3789
- Gustafson-Svard, C., Lilja, I., Hallbrook, O. and Sjodahl, R. (1996) Cyclooxygenase-1 and cyclooxygenase-2 gene expression in human colorectal adenocarcinomas and in azoxymethane induced colonic tumors in rats. *Gut* **38**, 79–84
- Sheehan, K. M., Sheehan, K., O'Donoghue, D. P., MacSweeney, F., Conroy, R. M., Fitzgerald, D. J. and Murray, F. E. (1999) The relationship between cyclooxygenase-2 expression and colorectal cancer. *J. Am. Med. Ass.* **282**, 1254–1257
- Oshima, M., Dinchuk, J. E., Kargman, S. L., Oshima, H., Hancock, B., Kwong, E., Trzaskos, J. M., Evans, J. L. and Taketo, M. M. (1996) Suppression of intestinal polyposis in *Apc^{Δ716}* knockout mice by inhibition of cyclooxygenase 2 (PGHS-2). *Cell* **87**, 803–809
- Crofford, L. J., Wilder, R. L., Ristimaki, A. P., Sano, H., Remmers, E. F., Epps, H. R. and Hla, T. (1994) Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1 β , phorbol ester and corticosteroids. *J. Clin. Invest.* **93**, 1095–1101
- Gilroy, D. W., Colville-Nash, P. R., Willis, D., Chivers, J., Paul-Clark, M. J. and Willoughby, D. A. (1999) Inducible cyclooxygenase may have anti-inflammatory properties. *Nat. Med. (N.Y.)* **5**, 698–701
- Kutcher, W., Jones, D. A., Matsunami, N., Groden, J., McIntyre, T. M., Zimmerman, G. A., White, R. L. and Prescott, S. M. (1996) Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. *Proc. Natl. Acad. Sci. U.S.A.* **93**, 4816–4820
- Kosaka, T., Miyata, A., Ihara, H., Hara, S., Sugimoto, T., Takeda, O., Takahashi, E. and Tanabe, T. (1994) Characterization of the human gene (PTGS2) encoding prostaglandin-endoperoxide synthase-2. *Eur. J. Biochem.* **221**, 889–897
- Inoue, H., Yokoyama, C., Hara, S., Tone, Y. and Tanabe, T. (1995) Transcriptional regulation of human prostaglandin-endoperoxide synthase-2 gene by lipopolysaccharide and phorbol ester in vascular endothelial cells. Involvement of both nuclear factor for interleukin-6 expression site and cAMP response element. *J. Biol. Chem.* **270**, 24965–24971
- Roshak, A. K., Jackson, J. R., McGough, K., Chabot-Fletcher, M., Mochan, E. and Marshall, L. A. (1996) Manipulation of distinct NF κ B proteins alters interleukin-1 β -induced human rheumatoid synovial fibroblast prostaglandin E_2 formation. *J. Biol. Chem.* **271**, 31496–31501
- Inoue, H. and Tanabe, T. (1998) Transcriptional role of the nuclear factor kappa B site in the induction by lipopolysaccharide and suppression by dexamethasone of cyclooxygenase-2 in U937 cells. *Biochem. Biophys. Res. Commun.* **244**, 143–148
- Subbaramaiah, K., Altorki, N., Chung, W. J., Mestres, J. R., Sampat, A. and Dannenberg, A. J. (1999) Inhibition of cyclooxygenase-2 expression by p53. *J. Biol. Chem.* **274**, 10911–10915
- Widmann, C., Gibson, S., Jarpe, M. B. and Johnson, G. L. (1999) Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. *Physiol. Rev.* **79**, 143–180
- Tournier, C., Whitmarsh, A. J., Cavanagh, J., Barrett, T. and Davis, R. J. (1997) Mitogen-activated protein kinase kinase 7 is an activator of the c-Jun NH $_2$ -terminal kinase. *Proc. Natl. Acad. Sci. U.S.A.* **94**, 7337–7342
- Yao, Z., Diener, K., Wang, X. S., Zukowski, M., Matsumoto, G., Zhou, G., Mo, R., Sasaki, T., Nishina, H., Hui, C. C. et al. (1997) Activation of stress-activated protein kinases/c-Jun N-terminal protein kinases (SAPKs/JNKs) by a novel mitogen-activated protein kinase kinase (MKK7). *J. Biol. Chem.* **272**, 32378–32383
- Foltz, I. N., Gerl, R. E., Weiler, J. S., Luckach, M., Salmon, R. A. and Schrader, J. W. (1998) Human mitogen-activated protein kinase kinase 7 (MKK7) is a highly conserved c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) activated by environmental stresses and physiological stimuli. *J. Biol. Chem.* **273**, 9344–9351
- Tournier, C., Whitmarsh, A. J., Cavanagh, J., Barrett, T. and Davis, R. J. (1999) The MKK7 gene encodes a group of c-Jun NH $_2$ -terminal kinase kinases. *Mol. Cell. Biol.* **19**, 1569–1581
- Lin, A., Minden, A., Martinetto, H., Claret, F. X., Lange-Carter, C., Mercurio, F., Johnson, G. L. and Karin, M. (1995) Identification of a dual specificity kinase that activates the Jun kinases and p38-Mpk2. *Science* **268**, 286–290
- Han, J., Lee, J. D., Jiang, Y., Li, Z., Feng, L. and Ulevitch, R. J. (1996) Characterization of the structure and function of a novel MAP kinase kinase (MKK6). *J. Biol. Chem.* **271**, 2886–2891
- Mansour, S. J., Wayne, T. M., Hermann, A. S., Candia, J. M., Rong, S., Fukasawa, K., Vande Woude, G. F. and Ahn, N. G. (1994) Transformation of mammalian cells by constitutively active MAP kinase kinase. *Science* **265**, 966–970
- Foschi, M., Chari, S., Dunn, M. J. and Sorokin, A. (1997) Biphasic activation of p21^{ras} by endothelin-1 sequentially activates the ERK cascade and phosphatidylinositol 3-kinase. *EMBO J.* **16**, 6439–6451
- Huang, S., Jiang, Y., Nishida, E., Mathias, P., Lin, S., Ulevitch, R. J., Nemerow, G. R. and Han, J. (1997) Apoptosis signaling pathway in T cells is composed of ICE/Ced-3 family proteases and MAP kinase kinase 6b. *Immunity* **6**, 739–749
- Wang, Y., Huang, S., Sah, V. P., Ross, J., Brown, J. H., Han, J. and Chein, K. R. (1998) Cardiac muscle hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. *J. Biol. Chem.* **273**, 2161–2168
- Wang, W., Su, B., Sah, V. P., Brown, J. H., Han, J. and Chein, K. R. (1998) Cardiac hypertrophy induced by mitogen-activated protein kinase 7, a specific activator for c-Jun NH $_2$ -terminal kinase in ventricular muscle cells. *J. Biol. Chem.* **273**, 5423–5426
- Sraer, J.-D., Delarue, F., Hagege, J., Feunteun, J., Pinet, F., Nguyen, G. and Rondeau, E. (1996) Stable cell lines of T-SV40 immortalized human glomerular mesangial cells. *Kidney Int.* **49**, 267–270
- Chomczynski, P. and Sacchi, N. (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. *Anal. Biochem.* **162**, 156–159
- Kester, M., Coroneos, E., Thomas, P. J. and Dunn, M. J. (1994) Endothelin stimulates prostaglandin endoperoxide synthase-2 mRNA and protein synthesis through a tyrosine kinase-signaling pathway in rat mesangial cells. *J. Biol. Chem.* **269**, 22574–22580
- Bokemeyer, D., Sorokin, A., Yan, M., Ahn, N. G., Templeton, D. J. and Dunn, M. J. (1996) Induction of mitogen-activated protein kinase phosphatase 1 by the stress-activated protein kinase signaling pathway but not by extracellular signal-regulated kinase in fibroblasts. *J. Biol. Chem.* **271**, 639–642
- Molnar, M., Rigo, J., Romero, R. and Hertelendy, F. (1999) Oxytocin activates mitogen-activated protein kinase and up-regulates cyclooxygenase-2 and prostaglandin production in human myometrial cells. *Am. J. Obstet. Gynecol.* **181**, 42–49
- Adderley, S. R. and Fitzgerald, D. J. (1999) Oxidative damage of cardiomyocytes is limited by extracellular regulated kinases 1/2-mediated induction of cyclooxygenase-2. *J. Biol. Chem.* **274**, 5038–5046
- Xie, W. and Herschman, H. R. (1995) V-src induces prostaglandin synthase 2 gene expression by activation of the c-Jun N-terminal kinase and the c-Jun transcription factor. *J. Biol. Chem.* **270**, 27622–27628
- Nakajima, T., Kinoshita, S., Sasagawa, T., Sasaki, K., Naruto, M., Kishimoto, T. and Akira, S. (1993) Phosphorylation at threonine-235 by a ras-dependent mitogen-activated protein kinase cascade is essential for transcription factor NF-IL6. *Proc. Natl. Acad. Sci. U.S.A.* **90**, 2207–2211
- Metz, R. and Ziff, E. (1991) cAMP stimulates the C/EBP-related transcription factor rNFIL-6 to translocate to the nucleus and induce c-fos transcription. *Genes Dev.* **5**, 1754–1766
- Xie, W. and Herschman, H. R. (1996) Transcriptional regulation of prostaglandin synthase 2 gene expression by platelet-derived growth factor and serum. *J. Biol. Chem.* **271**, 31742–31748
- Guan, Z., Buckman, S. Y., Pentland, A. P., Templeton, D. J. and Morrison, A. (1998) Induction of cyclooxygenase-2 by the activated MEK1-SEK1/MKK4-p38 mitogen-activated protein kinase pathway. *J. Biol. Chem.* **273**, 12901–12908
- Minden, A., Lin, A., Smeal, T., Cobb, M., Davis, R. J. and Karin, M. (1994) c-Jun N-terminal phosphorylation correlates with activation of the JNK subgroup but not the ERK subgroup of mitogen-activated protein kinases. *Mol. Cell. Biol.* **14**, 6683–6688
- Lee, W., Haslinger, A., Karin, M. and Tjian, R. (1987) Activation of transcription by two factors that bind promoter and enhancer sequences of the human metallothionein gene and SV40. *Nature (London)* **325**, 368–372
- Pedraza-Alva, G., Zingg, J. M. and Jost, J. P. (1994) AP-1 binds to a putative cAMP response element of the MyoD1 promoter and negatively modulates MyoD1 expression in dividing myoblasts. *J. Biol. Chem.* **269**, 6978–6985
- Subbaramaiah, K., Chung, W. J. and Dannenberg, A. J. (1998) Ceramide regulates the transcription of cyclooxygenase-2. Evidence for the involvement of extracellular signal-regulated kinase/c-Jun N-terminal kinase and p38 mitogen-activated protein kinase pathways. *J. Biol. Chem.* **273**, 32943–32949
- Licato, L. L., Keku, T., Wurzelmann, J. I., Murray, S. C., Woosley, J. T., Sandler, R. S. and Brenner, D. A. (1997) In vivo activation of mitogen-activated protein kinases in rat intestinal neoplasia. *Gastroenterology* **113**, 1589–1598

- 42 Sebolt-Leopold, J. S., Dudley, D. T., Herrera, R., Van Becelaere, K., Wiland, A., Gowan, R. C., Teclé, H., Barrett, S. D., Bridges, A., Przybranowski, S. et al. (1999) Blockade of the MAP kinase pathway suppresses growth of colon tumors *in vivo*. *Nat. Med. (N.Y.)* **5**, 810–816
- 43 Wang, Q., Ding, Q., Dong, Z., Ehlers, R. A. and Evers, B. M. (2000) Downregulation of mitogen-activated protein kinases in human colon cancers. *Anticancer Res.* **20**, 75–83
- 44 Atten, M. J., Attar, B. M. and Holian, O. (1995) Decreased MAP kinase activity in human gastric adenocarcinoma. *Biochem. Biophys. Res. Commun.* **212**, 1001–1006
- 45 Eggstein, S., Franke, M., Kutschka, I., Manthey, G., von Specht, B. U., Ruf, G. and Farthmann, E. H. (1999) Expression and activity of mitogen activated protein kinases in human colorectal carcinoma. *Gut* **44**, 834–838
- 46 Tibbles, L. A. and Woodgett, J. R. (1999) The stress-activated protein kinase pathways. *Cell. Mol. Life Sci.* **55**, 1230–1254

Received 25 April 2000/11 August 2000; accepted 19 September 2000